FX.co ★ Fennec' Pedmarqsi Gets Support From NICE For Cisplatin-Induced Hearing Loss Prevention

Fennec Pharmaceuticals Inc. (FENC) announced on Friday that the National Institute for Health and Care Excellence (NICE) has endorsed Pedmarqsi for the prevention of hearing loss caused by Cisplatin in patients with localized, non-metastatic solid tumors. The company noted that findings from two open-label, randomized Phase 3 trials—SIOPEL 6 and the Clinical Oncology Group Protocol ACCL0431—showed approximately a 50% reduction in the incidence of hearing loss caused by cisplatin in patients treated with a combination of cisplatin and sodium thiosulfate.